MannKind Is Compliant With MidCap's March Covenant But Will Face Challenges In The Future [Seeking Alpha]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Seeking Alpha
When MannKind (NASDAQ:MNKDAccording to my modeling, MannKind’s Afrezza exceeded the minimum trailing 12-month net revenue requirement of $26,290,000 to remain compliant with MidCap's tranche 1 and 2 loan covenants. Afrezza's trailing 12-month net revenue was greater than $28,000,000 before taking into consideration new Brazil orders.In the near term, at least through June, Afrezza should be able to remain compliant with tranches 1 and 2. However, if MannKind is considering drawing the third tranche of $25 million, the trailing net revenue increases substantially. For instance, at the end of July, to remain compliant for tranches 1 and 2, trailing net revenue must exceed $29 million.In addition, to qualify for the third tranche, the trailing 12-month net revenue must exceed $36 million starting in July and that United Therapeutics (NASDAQ:UTHR8-K on December 18, 2019United Therapeutics has received positive clinical data on the Phase 1b BREEZE trial and (y) Agent has received evidence
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]Yahoo! Finance
- MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney DiseaseGlobeNewswire
- MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
- MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
MNKD
Earnings
- 11/5/25 - Beat
MNKD
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/2/25 - Form 144
- MNKD's page on the SEC website